Abstract:Introduction: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer. However, pathogenetic mechanisms, molecular determinants of recurrence, and predictive biomarkers for first-line treatment (anti-PD-(L)1 plus bevacizumab) in liver cancer remain incompletely understood. Materials and methods: Targeted next-generation sequencing (tNGS) (a 603-cancer-gene panel) was applied for the genomic profiling of 232 hepatocellular carcinoma (HCC) and 22 intrahepatic cholangiocarcinoma (ICC) patients, among which 47 unresectable/metastatic HCC patients underwent anti-PD-1 plus bevacizumab therapy. Genomic alterations were estimated for their association with vascular invasion (VI), location of onset, recurrence, overall survival (OS), recurrence-free survival (RFS), and anti-PD-1 plus bevacizumab therapy response. Results: The genomic landscape exhibited that the most commonly altered genes in HCC were TP53 , FAT3 , PDE4DIP , KMT2C , FAT1 , and MYO18A , while TP53 , FAT1 , FAT3 , PDE4DIP , ROS1 , and GALNT11 were frequently altered in ICC; notably, KRAS (18.18% vs. 1.29%) and BAP1 (13.64% vs. 1.29%) alterations were significantly more prevalent in ICC. Comparison analysis demonstrated the distinct clinicopathological/genomic characterizations between Chinese and Western HCC cohorts. Genomic profiling of HCC underlying VI showed that LDLR , MSH2 , KDM5D , PDE3A , and FOXO1 were frequently altered in the VI group compared to patients without VIs. Compared to the right hepatic lobes of HCC patients, the left hepatic lobe of HCC patients had superior OS (median OS: 36.77 months vs. unreached, p < 0.05). By further comparison, Notch signaling pathway-related alterations were significantly prevalent among the right hepatic lobes of HCC patients. Of note, multivariate Cox regression analysis showed that altered RB1 , NOTCH3 , MGA , SYNE1 , and ZFHX3 , as independent prognostic factors, were significantly correlated with the OS of HCC patients. Furthermore, altered LATS1 was abundantly enriched in the HCC-recurrent group, and impressively, it was independent of clinicopathological features in predicting RFS (median RFS of altered type vs. wild-type: 5.57 months vs. 22.47 months, p < 0.01). Regarding those treated HCC patients, TMB value, altered PTPRZ1 , and cell cycle-related alterations were identified to be positively associated with the objective response rate (ORR), but KMT2D alterations were negatively correlated with ORR. In addition, altered KMT2D and cell cycle signaling were significantly associated with reduced and increased time to progression-free survival (PFS), respectively. Conclusion: Comprehensive genomic profiling deciphered distinct molecular characterizations underlying VI, location of onset, recurrence, and survival time in liver cancer. The identification of novel genetic predictors of response to anti-PD-1 plus bevacizumab in HCC facilitated the development of an evidence-based approach to therapy.

Clinically Significant Shared and Distinct Genomic Alterations in Chinese and Western Patients with Intrahepatic Cholangiocarcinoma

Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma

Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.

Abstract 3878: The different genetic alterations between Western and Chinese samples indicate alternate pathways of prostate cancer development

The Different Genetic Alterations Between Western and Chinese Prostate Cancers and the Underlying Mechanisms.

Abstract 4607: G1/S Transition-Related Gene Mutations Associated with Survival of Hepatocellular Carcinoma Patients

Comprehensive Molecular Profiling of Intrahepatic Cholangiocarcinoma in the Chinese Population and Therapeutic Experience

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Characteristics of Genomic Alterations in Chinese Cholangiocarcinoma Patients.

Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma

Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients

Molecular Profiling and Prognostic Analysis in Chinese Cholangiocarcinoma: an Observational, Retrospective Single-Center Study.

Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases

Molecular profiling of Chinese patients with advanced hepatocellular carcinoma using circulating tumor DNA.

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer

Deep Whole-Genome Analysis of 494 Hepatocellular Carcinomas

Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population

Analysis of genomic alterations in pan-cancer from a large real-world Chinese population.

Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis

Whole-exome Mutational and Transcriptional Landscapes of Combined Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma Reveal Molecular Diversity

Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses